Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation
Standard
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. / van der Sluis, Inge M; Vrooman, Lynda M; Pieters, Rob; Baruchel, Andre; Escherich, Gabriele; Goulden, Nicholas; Mondelaers, Veerle; de Toledo, Jose Sanchez; Rizzari, Carmelo; Silverman, Lewis B; Whitlock, James A.
In: HAEMATOLOGICA, Vol. 101, No. 3, 03.2016, p. 279-85.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation
AU - van der Sluis, Inge M
AU - Vrooman, Lynda M
AU - Pieters, Rob
AU - Baruchel, Andre
AU - Escherich, Gabriele
AU - Goulden, Nicholas
AU - Mondelaers, Veerle
AU - de Toledo, Jose Sanchez
AU - Rizzari, Carmelo
AU - Silverman, Lewis B
AU - Whitlock, James A
N1 - Copyright© Ferrata Storti Foundation.
PY - 2016/3
Y1 - 2016/3
N2 - L-asparaginase is an integral component of therapy for acute lymphoblastic leukemia. However, asparaginase-related complications, including the development of hypersensitivity reactions, can limit its use in individual patients. Of considerable concern in the setting of clinical allergy is the development of neutralizing antibodies and associated asparaginase inactivity. Also problematic in the use of asparaginase is the potential for the development of silent inactivation, with the formation of neutralizing antibodies and reduced asparaginase activity in the absence of a clinically evident allergic reaction. Here we present guidelines for the identification and management of clinical hypersensitivity and silent inactivation with Escherichia coli- and Erwinia chrysanthemi- derived asparaginase preparations. These guidelines were developed by a consensus panel of experts following a review of the available published data. We provide a consensus of expert opinions on the role of serum asparaginase level assessment, indications for switching asparaginase preparation, and monitoring after change in asparaginase preparation.
AB - L-asparaginase is an integral component of therapy for acute lymphoblastic leukemia. However, asparaginase-related complications, including the development of hypersensitivity reactions, can limit its use in individual patients. Of considerable concern in the setting of clinical allergy is the development of neutralizing antibodies and associated asparaginase inactivity. Also problematic in the use of asparaginase is the potential for the development of silent inactivation, with the formation of neutralizing antibodies and reduced asparaginase activity in the absence of a clinically evident allergic reaction. Here we present guidelines for the identification and management of clinical hypersensitivity and silent inactivation with Escherichia coli- and Erwinia chrysanthemi- derived asparaginase preparations. These guidelines were developed by a consensus panel of experts following a review of the available published data. We provide a consensus of expert opinions on the role of serum asparaginase level assessment, indications for switching asparaginase preparation, and monitoring after change in asparaginase preparation.
U2 - 10.3324/haematol.2015.137380
DO - 10.3324/haematol.2015.137380
M3 - SCORING: Journal article
C2 - 26928249
VL - 101
SP - 279
EP - 285
JO - HAEMATOLOGICA
JF - HAEMATOLOGICA
SN - 0390-6078
IS - 3
ER -
